Agusaputra et. all, HTMJ Volume 17 nomer 1 ; 2019 11 HANG TUAH MEDICAL JOURNAL www.journal-medical.hangtuah.ac.id Review Artikel Potensi Pemeriksaan PA : EGFR, KRAS, ALK-EML4, MET, mTOR, FGFR-1 ERCC- 1, FGFR-1, MMR-1, TUBB-3, pada kanker Paru. HARMAN AGUSAPUTRA, LOO HARYANTO Fakultas Kedokteran Universitas Wijaya Kusuma Surabaya email: harman_74as@yahoo.com ABSTRACT Lung cancer has been one of problematic diseases in the world with the highest death rate compares to other kinds of cancer which is triggered by highly consumptions of cigarettes, pollutants, tuberculosis comorbid, and HIV according to data found in Indonesia. In Indonesia, Lung cancer has a lower survival rate compares to many develop countries in a year such as in the United States of America (43%). Meanwhile Indonesia has survival rates between 18-24% in Semarang and Makassar. Several factors which are able to support a patient’s lifespan would be a patient’s nutrition status, economy, more modern diagnostic, and therapy. The progress of molecular protein science in fact is developed from tissue cells which is a challenging growth from genetic and anatomy pathology. Nowadays, the anatomy pathology advancement relatively attain the limited targeted therapy examination which are EGFR and PDL-1. Hopefully, it will develop more likely to KRAS, ALK-EML4, MET, mTOR, FGFR-1 ERCC-1, FGFR-1, MMR-1, TUBB-3 by becoming a priority, and therefore, there are needs to prepare a proper algorithm for the effectiveness of a medication. This scientific research aims to initiate knowledge and anatomy pathology examine identification not only to certain types of tumor, but it goes beyond the targeted therapy and helps to decide on giving the chemotherapy medicine. Keyword: Lung cancer, therapy, molecular protein Abstrak Kanker paru merupakan permasalahan dunia juga di Indonesia, dengan angka kematian tertinggi dibanding kanker yang lain, dan data di Indonesia, pola konsumptif rokok yang tinggi, polutan, dan komorbid penyakit tuberculosis, HIV turut berkontribusi. Kanker paru di Indonesia, mempunyai angka survival yang lebih rendah dalam 1 tahun, dinbanding di negara maju spt contoh di ameriksa sebesar 43%, di Indonesia 18-24% (semarang dan makasar). Banyak faktor yang menunjang menjadi lebih